Research Studies

Renal Disease Research Institute (RDRI) is a research entity affiliated with Dallas Nephrology Associates. For more than 50 years, Dallas Nephrology Associates has been caring for patients with kidney disease, hypertension, transplants and complicated electrolyte disorders. The Research Institute allows us to conduct clinical trials that will improve our future ability to treat kidney disease and give our patients the opportunity to receive cutting-edge therapy.  At RDRI, there is significant ethical oversight of this entity through RDRI’s Board of Managers and Scientific Review Committee.

Choosing to participate in a study is an important personal decision. Are you interested in participating in a study?  Talk with your doctor and family members or friends about deciding to join a study.

Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With ANCA-associated Vasculitis

Protocol Name: Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With ANCA-associated Vasculitis

Protocol #: 20220159

Indication: ANCA associated Vasculitis

GFR: ≥15

Principal Investigator: Ankit Mehta, MD

Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204

DETAILS >

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin in Participants with Chronic Kidney Disease and High Blood Pressure

Protocol Name: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin in Participants with Chronic Kidney Disease and High Blood Pressure

Protocol #: D6972C00002

Indication: CKD & HTN

GFR: 30-75

Principal Investigator: Ankit Mehta, MD

Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246

DETAILS >

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants with APOL1-Mediated Kidney Disease

Protocol Name: Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants with APOL1-Mediated Kidney Disease

Protocol #: D6800C00005

Indication: APOL1-Mediated Proteinuric Kidney Disease

GFR: ≥ 25

Principal Investigator: Akinwande Akinfolarin

Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246

DETAILS >

Does aldosterone synthase inhibition prevent kidney disease progression, heart failure or cardiovascular death?

Protocol Name: Does aldosterone synthase inhibition prevent kidney disease progression, heart failure or cardiovascular death?

Protocol #: EASi-Kidney

Indication: CKD

GFR: 20-90

DETAILS >

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure.

Protocol Name: A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure.

Protocol #: D6972C00003

Indication: CKD & HTN

GFR: 30-89

Principal Investigator: Ankit Mehta, MD

Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246

DETAILS >

Phase 2b Open-label Study of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease

Protocol Name: Phase 2b Open-label Study of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease

Protocol #: VX24-147-202

Indication: APOL1-Mediated Proteinuric Kidney Disease

GFR: ≥25 to ≤75

Principal Investigator: Bernard Fischbach, MD

Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246

DETAILS >

A Phase 3, Randomized, Double-Blind,Placebo-Controlled Study of Povetacicept in Adults with IgA Nephropathy (Rainier)

Protocol Name: A Phase 3, Randomized, Double-Blind,Placebo-Controlled Study of Povetacicept in Adults with IgA Nephropathy (Rainier)

Protocol #: AIS-D08 RANIER

Indication: IgA Nephropathy

GFR: ≥30

DETAILS >

Efficacy and safety of extended TARPEYO® treatment >9 months in adult patients with primary IgA nephropathy

Protocol Name: Efficacy and safety of extended TARPEYO® treatment >9 months in adult patients with primary IgA nephropathy

Protocol #: Nef-403 (NefXtend)

Indication: IgA Nephropathy

DETAILS >

Expanding and Promoting Alternative Care and Knowledge in Decision-Making: The ExPAND Study

Protocol Name: Expanding and Promoting Alternative Care and Knowledge in Decision-Making: The ExPAND Study (Improving Shared Decision-Making and Access to Non-Dialytic Treatment for People with Kidney Disease)

Protocol #: PCORI ExPAND

Indication: Late Stage CKD

GFR: <20

DETAILS >

Study of Efficacy and Safety of Iptacopan in Participants With Active Lupus Nephritis Class III-IV, +/​- V

Protocol Name: Study of Efficacy and Safety of Iptacopan in Participants With Active Lupus Nephritis Class III-IV, +/​- V

Protocol #: CLNP023K12201

Indication: Lupus Nephritis

GFR: ≥ 25

DETAILS >

Observational Study Protocol – Fabry Disease Registry

Protocol Name: Observational Study Protocol – Fabry Disease Registry

Protocol #: DIREGC07006

Indication: Fabry Disease

Principal Investigator: Ankit Mehta, MD

Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204

DETAILS >

ACTION3: Study of Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (Dimerix B)

Protocol Name: ACTION3: A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

Protocol #: DMX-200-301

Indication: FSGS

GFR: > 30

Primary Investigator: Kim Rice, MD

Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204

DETAILS >

Phase 2/​3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease (Vertex)

Protocol Name: Phase 2/​3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease

Protocol #: VX21-147-301

Indication: APOL1-Mediated Proteinuric Kidney Disease

Primary Investigator: Bernard Fischbach, MD

Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246

DETAILS >

Clinical research studies are necessary to prove that a medicine or treatment is both safe and effective.